Home » Poolbeg Pharma (POLB)

Category Archives: Poolbeg Pharma (POLB)

#POLB Poolbeg Pharma – Poolbeg signs option for new vaccine candidate

6 December 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an Option Agreement to licence MelioVac, a vaccine for melioidosis, with University College Dublin (‘UCD’) and its inventor, Associate Professor Siobhán McClean , through NovaUCD, the university’s knowledge transfer office.  

The Company will continue its due diligence on MelioVac, a preclinical asset and recipient of a Wellcome Trust Award to aid its development, as well as 5 of other potential vaccine candidates discovered by Associate Professor McClean and her team, for the duration of the Option Agreement, prior to signing a ‘Licence Agreement’.

Dr McClean is Associate Professor and Head of Biochemistry at the UCD School of Biomolecular and Biomedical Science.   Dr McClean completed her BSc in Biochemistry in UCD and received her PhD from Imperial College London. Her research focuses on lung infections which led her to develop a platform technology to identify proteins that bacteria use to attach to human cells. These proteins have proved to be excellent vaccine candidates. Dr McClean completed some of the original research to identify the antigens associated with the Melioidosis Vaccine at TU Dublin.

Poolbeg Pharma has identified melioidosis as an infectious disease of interest due to its rising incidence around the world and because there is currently no approved vaccine available. Concerns are growing about global warming contributing to the spread of the disease to traditionally non-tropical areas.

Melioidosis, also known as Whitmore’s disease, is an infectious disease caused by the bacterium Burkholderia pseudomallei, commonly found in the soil and surface groundwater of many tropical and subtropical regions, with diverse clinical presentations including pneumonia and severe sepsis with multiple organ abscesses. Incidence of the disease is widespread in South-East Asia, Northern Australia and India, with climate change having a substantial impact on the spread of the disease to new areas such as Brazil. There are an estimated 165,000 cases of melioidosis each year, of which as many as 89,000 (54%) are estimated to be fatal.

Other potential vaccine candidates that the Company is evaluating include those for Klebsiella pneumoniae,Escherichia coli (O157), Burkholderia cepacia complex, Pseudomonas aeruginosa and Acinetobacter baumannii.

 

Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:

“Melioidosis offers Poolbeg an opportunity to expand our portfolio of infectious disease assets, as promised at IPO. This is a disease which presents a dangerous and underappreciated threat to human health which currently has no approved vaccine and a very high mortality rate. If we can take MelioVac through clinical development to Phase II ready, it has the potential to generate significant returns for investors in the short-term while contributing to the global response to the threat of infectious diseases with an unmet medical need. We are excited by the potential of the MelioVac opportunity along with the other vaccine candidates in the UCD portfolio.”

 

Siobhán McClean, Associate Professor at the UCD School of Biomolecular and Biomedical Science and inventor of MelioVac , said:

“We are passionate about developing a vaccine against Melioidosis. Poolbeg Pharma is a great potential partner to work with, bringing its experience of vaccine development and industry connections to our innovative science. On the basis that a license is taken, it would be a great to see the development of MelioVac and other candidates, and contribute significantly to the world’s renewed fight against infectious diseases.”

– Ends –

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (as implemented into English law) (“MAR”). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

  Enquiries

 

Poolbeg Pharma Plc

Jeremy Skillington, CEO

Ian O’Connell, CFO

 

+353 (0) 1 644 0007

finnCap Ltd (Nominated Adviser & Joint Broker)

Geoff Nash, James Thompson, Charlie Beeson,

Richard ChambersSunila de Silva (ECM)

 

+44 (0) 20 7220 0500

Arden Partners PLC (Joint Broker)

John Lewellyn-Lloyd, Louisa Waddell

 

+44 (0) 207 614 5900

J&E Davy (Joint Broker)

Anthony Farrell, Niall Gilchrist

+353 (0) 1 679 6363

Instinctif Partners

Melanie Toyne Sewell, Rozi Morris, Tim Field

+44 (0) 20 7457 2020

poolbeg@instinctif.com

#POLB Poolbeg Pharma – Shares Spotlight

Take a look at this issue of shares spotlight which features Poolbeg Pharma on page 14-15.

#POLB Poolbeg Pharma – Scientific Advisory Board Appointment

25 November, 2021- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has appointed Professor Daniel Hoft to its Scientific Advisory Board .

Prof Hoft, M.D., Ph.D. is the Dianna and J. Joseph Adorjan Endowed Chair of Infectious Diseases and Immunology, and Director of the Division of Infectious Diseases, Allergy & Immunology at Saint Louis University (SLU) School of Medicine. He has been working in immunology and infectious diseases for 32 years. Prof Hoft has published over 140 peer reviewed scientific publications.

Prof Hoft will join the Scientific Advisory Board alongside Dr Elaine Sullivan and Prof Luke O’Neill and with his extensive background in infectious disease, immunology, and vaccinology, will guide the Company on its asset development programmes. Prof Hoft will also work with the Company to scout for prospective in-licencing opportunities.

Prof Hoft is heavily involved in vaccine development research, especially for pandemic influenza and tuberculosis which has seen him undertake pioneering work in T-cell targeting vaccines which is particularly relevant to the Company’s Vaccine Discovery Platform. He is Principal Investigator of the SLU’s Vaccine & Treatment Evaluation Unit (VTEU), one of ten US National Institutes of Health (NIH) centers, placing it among an elite group of top academic centers conducting clinical trials of novel vaccines for global protection against future pandemic challenges. Since the SARS-CoV-2 pandemic the SLU VTEU led by Prof Hoft has featured prominently in the urgent COVID-19 vaccine development and Prof Hoft is the VTEU protocol chair for a first-in-human phase I trial of a novel COVID-19 vaccine. He has received numerous awards from NIH, US Department of Defense, and the Bill & Melinda Gates Foundation and is a regular advisor to the World Health Organisation.

Read Prof Hoft’s full bio on Poolbeg’s website .

Jeremy Skillington, PhD, CEO of Poolbeg Pharma,  said: “Prof Hoft is a great addition to the Poolbeg Scientific Advisory Board, joining Dr Elaine Sullivan and Prof Luke O’Neill. His expertise in infectious disease, particularly with severe influenza and vaccine development will be invaluable as we develop Poolbeg’s pipeline of assets. He will also work with the Company to scout for prospective assets to in-licence and develop. Prof Hoft is a widely respected specialist within our industry and we look forward to working with him as we continue our growth journey.” 

Prof Daniel Hoft, M.D., Ph.D., commented:

“Poolbeg has an interesting portfolio of assets within infectious disease with an exciting lead asset, POLB 001. Coupled with its unique access to 20 years’ of human viral challenge study data, means its approach has real potential in this space. I look forward to helping support the business as it develops.”

– Ends –

 Enquiries

 

Poolbeg Pharma Plc

Jeremy Skillington, CEO

Ian O’Connell, CFO

 

+353 (0) 1 644 0007

finnCap Ltd (Nominated Adviser & Joint Broker)

Geoff Nash, James Thompson, Charlie Beeson,

Richard Chambers, Sunila de Silva (ECM)

 

 

+44 (0) 20 7220 0500

Arden Partners PLC (Joint Broker)

John Lewellyn-Lloyd, Louisa Waddell

 

 

+44 (0) 207 614 5900

J&E Davy (Joint Broker)

Anthony Farrell, Niall Gilchrist

 

+353 (0) 1 679 6363

Instinctif Partners

Melanie Toyne Sewell, Rozi Morris, Tim Field

+44 (0) 20 7457 2020

poolbeg@instinctif.com

#POLB Poolbeg Pharma – Update on POLB 001 Clinical Development

18 November 2021 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, is pleased to provide an update on the clinical development progress of its lead asset, POLB 001, a small molecule immunomodulator for the treatment of severe influenza.

The Company intends to commence the Phase Ib human challenge study of POLB 001 in June 2022 which will be a key step in the molecule’s development. To enable this study, the Company has signed a Letter of Intent to retain the Centre for Human Drug Research (CHDR) to run the challenge study and signed an agreement with SEDA Pharmaceutical Development Services for drug formulation services. A vendor has also been selected for GMP* manufacturing of POLB 001.

In this study, clinical researchers from CHDR will stimulate a healthy volunteer’s immune system with bacterial lipopolysaccharide (LPS) in a safe and controlled clinical environment. The study will provide key human data on the efficacy of POLB 001 in dampening the immune response in otherwise healthy volunteers. It will use LPS to simulate the effects of treating severe influenza in the volunteers without the virus itself being present. In cases of severe influenza, the body produces an over-heightened immune response that can cause more damage to the body than the virus itself. POLB 001’s mode of action is to reduce this hyper-immune response. The design of the study (the study protocol) is expected to be finalised by the end of Q1 2022.

In advance of the Phase Ib study commencing, the Company has completed the manufacturing of a non-GMP* batch of POLB 001 which is on hand for any non-clinical (not administered to humans) requirements, such as formulation. This is also an important step in validating the manufacturing process. On this basis, manufacturing can now be scaled up as required as the clinical development phase progresses. The Company will now move towards manufacturing GMP* grade POLB 001 material needed for the LPS challenge study and has similarly selected a vendor for this work.

 

Jeremy Skillington, PhD, CEO of Poolbeg Pharma said:

“We are delighted to be progressing our POLB 001 asset as planned, with preparatory steps in motion in advance of the LPS human challenge study clinical trial. We have selected experienced partners in SEDA to formulate the product, and CHDR to run our LPS human challenge study. The clinical study is expected to commence in June 2022, as detailed at IPO. With our capital light and early monetisation model, we are actively developing infectious disease assets with modest investment where they can be monetised / licenced to Big Pharma. We will continue to provide updates as we progress the programme.”

 

*Good Manufacturing Practice (GMP) is the regulatory code of standards that a medicine’s manufacturer must meet in its production processes to enable administration to humans.

 

Enquiries

 

Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O’Connell, CFO
+353 (0) 1 644 0007
finnCap Ltd (Nominated Adviser & Joint Broker)
Geoff Nash, James Thompson, Charlie Beeson,
Richard Chambers, Sunila de Silva (ECM)
+44 (0) 20 7220 0500
Arden Partners PLC (Joint Broker)
John Lewellyn-Lloyd, Louisa Waddell
+44 (0) 207 614 5900
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist
+353 (0) 1 679 6363
Instinctif Partners
Melanie Toyne Sewell, Rozi Morris, Tim Field
+44 (0) 20 7457 2020
poolbeg@instinctif.com

Poolbeg Pharma #POLB – Exec Chairman Cathal Friel & CEO Jeremy Skillington talk to Alan Green

Poolbeg Pharma #POLB Exec Chairman Cathal Friel and CEO Jeremy Skillington talk to Alan Green about the company’s ‘capital light’ business model. We discuss the POLB 001 asset, spun out of Open Orphan #ORPH, data samples, the PredictViral and vaccine discovery platforms plus further pipeline products. Cathal discusses the company cash position, and Jeremy highlights the upcoming value inflection points for investors and shareholders.

Alan Green discusses ECR Minerals #ECR, with a tribute to CEO Craig Brown, plus Poolbeg Pharma #POLB on this week’s Stockbox Research talk

Alan Green discusses ECR Minerals #ECR, with a tribute to CEO Craig Brown, plus Poolbeg Pharma #POLB on this week’s Stockbox Research talk

#POLB Poolbeg Pharma – PredictViral™ Patent update

4 October 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, provides an update on new patent filings for its PredictViral™ platform that estimates disease severity and contagiousness in people who are recently infected with a respiratory virus.

Expanding on existing PredictViral™ IP, these latest patent applications have been submitted in the UK and aims to protect a method of predicting whether an individual exposed to a respiratory virus (such as Influenza, RSV, hRV) will have a higher severity of disease and / or be more likely to be contagious. The Company will continue to focus on expanding its IP portfolio as required. 

hVIVO (part of Open Orphan plc ) filed these predictive biomarker patent applications on behalf of Poolbeg and as agreed as part of the demerger process and as outlined in Poolbeg’s IPO Admission Document, ownership will ultimately reside with Poolbeg which will continue to commercialise the platform. This will provide clinicians with a risk score for recently infected patients who are likely to experience a severe form of disease. Identifying viral infections early and triaging patients based on likely severity is vitally important in optimising clinical outcomes and can be particularly important in diseases such as influenza where there is a limited window for successful treatment early in the disease. The Company will continue to focus on expanding its IP portfolio as required. 

Poolbeg Pharma believes that the PredictViral™ platform offers diagnostic companies a transformative product that will enhance clinical decision-making while differentiating their platforms at a time of intense competition in this market. Discussions are ongoing with multiple parties to continue this technology’s development and license it for commercial use. The global market for diagnostic tools for infectious disease is rapidly growing and is expected to be worth over $19 billion per annum by 2025.

Jeremy Skillington, PhD, CEO of Poolbeg Pharma said:

“Protecting the IP for such an innovative disease severity platform as PredictViral™ is important and key to our strategy of commercialising this cutting-edge technology. 

PredictViral™ will provide valuable information for assessing the best course of treatment for viral disease. It has the potential to help early interventions when needed and to reduce the spread of disease, even amongst those who are unaware they are infected – the importance of which has become very clear during the COVID-19 global pandemic.”

– Ends –

  Enquiries

 

Poolbeg Pharma Plc

Jeremy Skillington, CEO

Ian O’Connell, CFO

 

+353 (0) 1 644 0007

finnCap Ltd (Nominated Adviser & Joint Broker)

Geoff Nash, James Thompson, Charlie Beeson  

 

 

+44 (0) 20 7220 0500

Arden Partners PLC (Joint Broker)

John Lewellyn-Lloyd, Louisa Waddell, Oscair McGrath

 

 

+44 (0) 207 614 5900

J&E Davy (Joint Broker)

Anthony Farrell, Niall Gilchrist

 

+353 (0) 1 679 6363

Instinctif Partners

Melanie Toyne Sewell, Rozi Morris, Tim Field

+44 (0) 20 7457 2020

poolbeg@instinctif.com

Poolbeg Pharma #POLB – RNA sequencing ahead of AI analysis programme

polb

RNA sequencing ahead of pioneering AI analysis programme

7 October 2021 – Poolbeg Pharma (AIM: POLB), Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has partnered with leading global biopharma services company, Eurofins Genomics (‘Eurofins’), to complete RNA sequencing for Poolbeg of Respiratory Syncytial Virus (RSV) disease progression samples from human viral challenge studies.

This deep sequencing work is a key step leading to Poolbeg commencing Artificial Intelligence (AI) analysis of its RSV data and will mean that it then has full immunological datasets for RSV, as well as influenza, which are ready to use with AI platforms to identify drug targets and products for influenza and RSV indications. The Company already has RNA sequencing data for influenza. This data is unique as it covers the full disease cycle and presents significant opportunities to unlock insights into these diseases which will magnify the power of the AI analysis.

The project with Eurofins is expected to be completed by the end of 2021 and will involve next generation RNA sequencing of RSV transcriptomics, or disease progression data, which enables the tracking of the biology of immune responses in molecular detail during infection.

Sequencing of the samples will be tailored for incorporation into AI algorithms which will be the first time that human challenge trial immune data has been analysed using AI, unlocking unique insights from the rich dataset that Poolbeg will translate into additional pipeline products which will be progressed using its capital light clinical structure. 

RSV is a contagious virus that affects the respiratory tract of children and at-risk older adults; in severe cases, it can cause pneumonia and other life-threatening breathing difficulties. RSV is a significant public health threat and is one of the leading causes of hospitalisation to at-risk older adults. There is currently no vaccine on the market for RSV.

Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:

“This is an exciting step in our AI data analysis programme. The deep genetic analysis of RSV progression will be key information to feed into AI drug and target discovery tools. We already have similar data for influenza so we will now have complete discovery datasets for both influenza and RSV.

Our AI analysis will be breaking new ground in data-driven drug discovery as it will be the first time that human challenge trial immune data is used in this way. Having the sequencing specially tailored to work with AI platforms will enable us to discover potential new drug candidates for both diseases in a quicker and more cost-effective way.”

  Enquiries

 

Poolbeg Pharma Plc

Jeremy Skillington, CEO

Ian O’Connell, CFO

 

+353 (0) 1 644 0007

finnCap Ltd (Nominated Adviser & Joint Broker)

Geoff Nash, James Thompson, Charlie Beeson 

Richard Chambers, Sunila de Silva (ECM)

 

 

+44 (0) 20 7220 0500

Arden Partners PLC (Joint Broker)

John Lewellyn-Lloyd, Louisa Waddell, Oscair McGrath

 

 

+44 (0) 207 614 5900

J&E Davy (Joint Broker)

Anthony Farrell, Niall Gilchrist

 

 

+353 (0) 1 679 6363

Instinctif Partners

Melanie Toyne Sewell, Rozi Morris, Tim Field

+44 (0) 20 7457 2020

poolbeg@instinctif.com

 

About Poolbeg Pharma

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a “one-stop shop” for Big Pharma seeking mid-stage products to licence or acquire.

The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.

With its initial assets from Open Orphan plc , an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. It already has a Phase II ready repositioned small molecule immunomodulator for severe influenza and a portfolio of other exciting assets. The Company plans to broaden this portfolio further going forward and is in active discussions with AI data analysis platforms to help accelerate the power of its human challenge model data and biobank.

For more information, please go to www.poolbegpharma.com

 

About Eurofins Genomic s

Eurofins Genomics is a global leader in genomic products and services .Eurofins Genomics, a member of the Eurofins Group with facilities in Europe, the United States and Asia, is an internationally leading provider of DNA sequencing services, next generation sequencing services, genotyping services, DNA synthesis products and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological and research markets. The company’s strength is its extensive customer base and high-quality services in industrial scale for the life science industries and academic research institutions around the world. For further information, please visit www.eurofinsgenomics.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

Poolbeg Pharma #POLB – Admission to AIM and First day of trading

Poolbeg Pharma (AIM: POLB), a clinical stage infectious disease pharmaceutical company with a capital light clinical model , is pleased to announce that admission of its entire issued share capital to trading on the AIM market of the London Stock Exchange will become effective and dealings will commence at 8.00 a.m. today under the ticker “POLB” and with the ISIN GB00BKPG7Z60 (“Admission”).

The full Admission Document is available to view on the Company’s website at www.poolbegpharma.com

IPO highlights

· Shares priced at 10p per share equating to a market capitalisation at Admission of £50m

· Oversubscribed fundraise which resulted in an increased raise from £20m to £25m despite some investor scale back

· Funds raised to be used primarily:

to fund clinical trial costs associated with development of the Company’s POLB 001 asset as a treatment for severe Influenza and potentially other areas with label extensions

work on advancing other portfolio assets to monetisation

to acquire and develop other infectious disease assets 

Company investment case

· Attractive lead asset – POLB 001 – A first-in-class, Phase II ready small molecule immunomodulator for severe influenza, addressing a significant unmet need for effective treatments (c. $800m addressable market)

· Wide asset portfolio – lead product has applications beyond Influenza plus PredictViral™ Biomarker platform for early prediction of severe disease (which has the potential to transform the way that infectious diseases are treated) and the Vaccine Discovery Platform harnessing data from the human challenge model 

· Valuable Data Access – licensed access to one of the largest infectious disease progression data and bio banks i.e. Open Orphan’s data and biobank, with the potential to interrogate the data with an AI data analysis platform (advanced discussions underway) to accelerate the identification of drug targets / products

· Rapidly expanding market – focused on infectious diseases, particularly Influenza and other viral diseases. The market is expected to exceed $250bn by 2025

·   Capital light and scalable business model – enables the Company to develop assets to be Phase II-ready quickly with modest investment where they can be monetised / licenced to big pharmaceutical companies

· Strong heritage – initial assets from Open Orphan plc (AIM: ORPH), a well-established, revenue generating business with more than 20 years of experience in infectious diseases and human challenge trials

· Experienced team – management team has a track record of delivery and creating value for shareholders

Jeremy Skillington, PhD, CEO of Poolbeg Pharma said:

“The IPO and funds raised have provided a strong platform to begin our rapid growth plan. With experienced management on board and the exciting assets acquired from Open Orphan, we look forward to delivering value to our shareholder base and generating innovation in the previously overlooked infectious disease space which is now one of the fastest growing markets and is expected to exceed $250bn by 2025.

“Our   capital light model versus conventional biotech has been well received by investors and the life sciences industry at large. We intend to drive business development through product in-licensing and acquisitions, which will provide continued momentum and value creation for our shareholders. At the core of our business, we are patient-focused and customer-led and plan to use our extensive network to become a ‘one-stop shop’ for big pharma, developing and partnering the infectious disease assets that they need.”

 

Cathal Friel, Chairman of Poolbeg Pharma commented:

“The listing of Poolbeg Pharma is a great opportunity to maximise the potential of some of Open Orphan’s key pharma assets and we have had excellent support from current and new shareholders.

“We have been deliberate in creating a company with a capital light model that can create excellent returns and value for its shareholders with substantially less risk than the traditional biotech model, which is why I was so excited to invest £500,000 personally in the IPO alongside incoming investors. We have assembled a leading management team with the tools and funding in place to deliver and are excited to now accelerate all our activities. At the heart of Poolbeg is the desire to improve infectious disease treatments for patients and provide valuable assets big pharma needs to improve patient care. It’s a win-win.”

– Ends –

  Enquiries

 

Poolbeg Pharma Plc

Jeremy Skillington, CEO

Ian O’Connell, CFO

 

+353 (0) 1 644 0007

finnCap Ltd (Nominated Adviser & Joint Broker)

Geoff Nash, James Thompson, Charlie Beeson 

 

 

+44 (0) 20 7220 0500

Arden Partners PLC (Joint Broker)

John Lewellyn-Lloyd, Richard Johnson, Oscair McGrath

 

 

+44 (0) 207 614 5900

J&E Davy (Joint Broker)

Anthony Farrell, Niall Gilchrist

 

+353 (0) 1 679 6363

Instinctif Partners

Melanie Toyne Sewell, Rozi Morris, Lewis Hill

+44 (0) 20 7457 2020

poolbeg@instinctif.com

 

About Poolbeg Pharma

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost   effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a “one-stop shop” for Big Pharma seeking mid-stage products to licence or acquire.

The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.

With its initial assets from Open Orphan plc, an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. It already has a Phase II ready repositioned small molecule immunomodulator for severe influenza and a portfolio of other exciting assets. The Company plans to broaden this portfolio further going forward and is in active discussions with AI data analysis platforms to help accelerate the power of its human challenge model data and biobank.

 

For more information, please go to www.poolbegpharma.com

Open Orphan #ORPH – AIM Schedule 1 update by Poolbeg Pharma plc

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , notes the AIM Schedule One released in relation to Poolbeg Pharma plc (“Poolbeg”) this morning, 14 July 2021 at 8.00 a.m. updating on Poolbeg’s admission to AIM and fundraising (“IPO”).

Poolbeg, a clinical-stage infectious diseases focused pharmaceutical company, was formed following a strategic decision by Open Orphan to demerge certain development assets from its core services led business, and has successfully raised £25 million by way of placing of new shares at 10p per share, giving Poolbeg a market valuation of £50 million at IPO.  

Admission and first day of trading is expected to be 19 July 2021.

For further information please contact:

 

Open Orphan plc

+353 (0) 1 644 0007

Cathal Friel, Executive Chairman

Arden Partners plc (Nominated Adviser and Joint Broker)

  +44 (0) 20 7614 5900

John Llewellyn-Lloyd / Richard Johnson / Oscair McGrath

finnCap plc (Joint Broker)

+44 (0) 20 7220 0500

Geoff Nash / James Thompson/ Richard Chambers

Davy (Euronext Growth Adviser and Joint Broker)

+353 (0) 1 679 6363

Anthony Farrell

Walbrook PR (Financial PR & IR)

+44 (0)20 7933 8780 or openorphan@walbrookpr.com

Paul McManus/ Sam Allen/ Louis Ashe-Jepson

+44 (0)7980 541 893 / +44 (0) 7502 558 258 / +44 (0) 7747 515393 

 

Notes to Editors  

Open Orphan plc

Open Orphan plc (London and Euronext: ORPH) is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The company provides services to Big Pharma, biotech and government/public health organisations.

Open Orphan runs challenge studies in London from both its 19-bedroom Whitechapel quarantine clinic, opened in February 2021, and its 24-bedroom QMB clinic which also has a highly specialised virology and immunology laboratory on-site. Open Orphan has a leading portfolio of eight human challenge study models for conditions such as RSV, flu, asthma and COPD. In addition, Open Orphan is also developing the world’s first COVID-19 human challenge study model as part of the Human Challenge Programme and has signed a reservation contract with the UK Government for the first three COVID-19 vaccine challenge studies.

Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company’s Disease in Motion® platform, this unique dataset includes clinical, immunological, virological and digital (wearable) biomarkers. The Disease in Motion platform has many potential applications across a wide variety of end users including big technology, wearables, pharma and biotech companies. Following COVID-19 there is now a renewed interest and investment in infectious diseases.

Open Orphan’s Paris office has been providing biometry, data management and statistics to its many European pharmaceutical clients for over 20 years. For over 15 years, the Company’s Netherlands office has been providing drug development consultancy and services, including CMC (chemistry, manufacturing and controls), PK and medical writing, to a broad range of European clients. Both offices are now also fully integrated with the London office and working on challenge study contracts as well as supporting third party trial contracts.

About Poolbeg Pharma

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which the Directors believe enables it to develop multiple products faster and more cost effectively than the traditional biotech model. Poolbeg has aspirations to become a “one-stop shop” for Big Pharma seeking mid-stage products to license or acquire.

Poolbeg is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing and exciting markets with expected market value of $250bn by 2025. Poolbeg is led by a team who have a track record of creating shareholder value, creating c. $1bn in shareholder value between them.

With its initial assets from Open Orphan plc and headquartered in London, Poolbeg is led by a team with proven capabilities in identifying, acquiring and accelerating assets through development to commercialisation. With access to knowledge, experience and clinical data from over 20 years of Influenza, RSV, HRV and SARS-CoV-2 human challenge trials, Poolbeg is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. It already has a Phase II ready repositioned small molecule immunomodulator for severe influenza and a portfolio of other exciting assets. The Company plans to broaden this portfolio further in the next 12 months and is in active discussions with AI data analysis platforms to help accelerate the power of its human challenge model data and biobank.

For more information, please go to www.poolbegpharma.com

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.